Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Gemcabene for the Treatment of Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Gemcabene for the Treatment of Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436420).
- Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00388154).
- Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence…
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer…
- Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01938716).
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01360593).
- Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).
- GEMINIIndependent statistical analysis of A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GEMINI IIIndependent statistical analysis of Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GEMINI LTSIndependent statistical analysis of An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GEMINI Study – A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: Complete Statistical AnalysisIndependent statistical analysis of GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GEMMIndependent statistical analysis of A Risky Sex Prevention Intervention for Middle School Age Minority Girls: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GEMNICIndependent statistical analysis of Gemfibrozil for Nicotine Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02638597).
- Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm: Complete Statistical AnalysisIndependent statistical analysis of Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemzar, Cisp, Sunitinib Urothelial Ca: Complete Statistical AnalysisIndependent statistical analysis of Gemzar, Cisp, Sunitinib Urothelial Ca: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00821327).
- GEN206Independent statistical analysis of Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00677924).
- Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT): Complete Statistical AnalysisIndependent statistical analysis of Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gene Signatures of Influenza Vaccine Responses in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Gene Signatures of Influenza Vaccine Responses in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03603509).
- Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) – Retinitis Pigmentosa GTPase Regulator (RPGR): Complete Statistical AnalysisIndependent statistical analysis of Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1: Complete Statistical AnalysisIndependent statistical analysis of Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02122952).
- Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD: Complete Statistical AnalysisIndependent statistical analysis of Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GENEr8-2Independent statistical analysis of Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg: primary endpoint results, effect estimate with confidence…
- GENEr8-AAV5+Independent statistical analysis of Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GENERATIONIndependent statistical analysis of Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3: Complete Statistical AnalysisIndependent statistical analysis of Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00878969).
- Genetic and Biochemical Markers of Interferon-Induced Depression.: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Biochemical Markers of Interferon-Induced Depression.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00252538).
- Genetic and Brain Mechanisms of Naltrexone’s Treatment Efficacy for Alcoholism: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920829).
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetic and Neural Factors in Alcohol-Related Cognition: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Neural Factors in Alcohol-Related Cognition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03725345).
- Genetic Basis for Variation in the Renal Elimination of Metformin: Complete Statistical AnalysisIndependent statistical analysis of Genetic Basis for Variation in the Renal Elimination of Metformin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00187720).